The healthcare and pharmaceuticals sector is witnessing selective demand improvement, particularly in organized tertiary care, driven by low bed penetration and increased insurance coverage. Pricing power is enhancing as input costs for APIs decline, although challenges from regulatory changes and competitive pressures remain. The macro backdrop, characterized by currency depreciation, is expected to bolster revenues for export-oriented firms, while potential raw material shortages pose risks to margin stability. Overall, the sector is positioned for moderate growth amid evolving dynamics.

SUNPHARMA DIVISLAB TORNTPHARM APOLLOHOSP CIPLA DRREDDY ZYDUSLIFE LUPIN MAXHEALTH MANKIND